Noonan Syndrome Market: How Is MEK Inhibition and Growth Hormone...

σε πρόσθεσε στο Health

2026-07-23 09:59:27 -

Noonan Syndrome Market: How Is MEK Inhibition and Growth Hormone Optimization Reshaping RASopathy Management?

Noonan syndrome — the autosomal dominant RASopathy characterized by short stature, distinctive facial features, congenital heart defects (pulmonary valve stenosis, hypertrophic cardiomyopathy), bleeding diathesis, and variable developmental delay resulting from germline mutations in PTPN11, SOS1, RAF1, KRAS, NRAS, BRAF, and other RAS-MAPK pathway genes — creating the most common...

0 Σχόλια 0 Μοιράστηκε 20 Views 0 Προεπισκόπηση